Key result
Elevated serum HMGB1 is linked to ~95% greater all-cause mortality risk in HFpEF.
Case-Control (n=276)
No
Hazard Ratio: 1.953 (95% CI 1.165–3.275)
p-value: p=0.011
Elevated serum HMGB1 levels are associated with atrial fibrillation and predict all-cause mortality in patients with HFpEF, suggesting its potential as a biomarker for risk stratification.
No takes yet. Share an insight, caveat, or question.
Elevated HMGB1 may indicate higher mortality risk; leaves open its value as a prognostic biomarker pending prospective validation.
Ge et al. (2026) conducted a case-control in Heart failure with preserved ejection fraction (HFpEF) (n=276). Elevated serum HMGB1 levels vs. Lower serum HMGB1 levels was evaluated on All-cause mortality (HR 1.953, 95% CI 1.165-3.275, p=0.011). Elevated serum HMGB1 levels were significantly associated with an increased risk of all-cause mortality (HR 1.953) in patients with heart failure with preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: